Objective:

To evaluate the clinical value of transrectal ultrasonography (TRUS)-guided 10-core plus fixed-point prostate biopsy combined with complexed prostate-specific antigen (cPSA) detection in the diagnosis of prostate cancer.

Methods:

cPSA was examined in 147 patients with suspected prostate cancer. All the patients underwent 10-core plus fixed-point prostate biopsy under the guidance of TRUS.

Results:

The accuracy of biopsy sampling was 100%. The positive rate of puncture biopsy was 38.8% (57/147) in 147 cases. The cutoff of cPSA was 7.6 ng/mL. There were 7

9 cases with cPSA more than or equal to 7.6 ng/mL. The specificity was 93.8% and the sensitivity was 72.2% for detecting prostate cancer when cPSA more than or equal to 7.6 ng/mL

and the positive rate of prostate biopsy was 68.4% (54/79). Puncture biopsy could be avoided in 46.3% (68/147) patients.

Conclusion:

TRUS-guided 10-core plus fixed-point prostate biopsy is a safe and reliable diagnostic method. When combined with cPSA with a cutoff of 7.6 ng/mL it can significantly increase the positive rate of prostate biopsy.